Gayatri BioOrganics Ltd: Zero Revenue Continues, FY26 Loss Widens to ₹1.11 Cr, Net Worth Negative ₹37 Cr

Gayatri BioOrganics Ltd reported a net loss of ₹42.05 Lakhs (₹0.42 Crores) for the quarter ended March 31, 2026, with zero revenue from operations. For the full fiscal year ended March 31, 2026, the net loss widened to ₹111.18 Lakhs (₹1.11 Crores), also on zero revenue.

Reader Takeaway: Zero revenue and expanding losses persist; negative net worth and promoter funding raise solvency questions.

What just happened (today’s filing)

Gayatri BioOrganics Ltd's Q4 FY26 results reveal a net loss of ₹0.42 crore, marking a significant 140.84% year-on-year increase in loss from ₹0.17 crore in the prior year's quarter.

Crucially, the company recorded zero revenue from operations in the quarter and for the entirety of the fiscal year FY26.

For the full fiscal year, net losses stood at ₹1.11 crore, a 53.04% increase from FY25's loss of ₹0.73 crore.

Basic Earnings Per Share (EPS) declined from ₹(0.09) to ₹(0.14) for FY26.

Why this matters

The persistent lack of revenue generation coupled with widening losses points to a deeply precarious financial state for Gayatri BioOrganics Ltd.

A negative net worth of ₹37 crore indicates severe financial distress and potential technical insolvency, placing the company's survival squarely on promoter funding.

The backstory (grounded)

The company currently possesses no Property, Plant & Equipment or inventory, signaling a complete absence of physical operational assets.

Significant disputed liabilities, including a substantial ₹7.47 Crore Income Tax demand and an ₹11.47 Crore Central Excise demand (inclusive of penalties), totaling over ₹24 Crore, loom over the company.

What changes now

• Shareholders are likely to face continued operational stagnation with no revenue generation in sight.
• The company's reliance on its promoters for essential funding to cover operational shortfalls and liabilities is set to increase.
• There is a heightened risk of further financial deterioration if the substantial disputed tax demands are upheld.
• The company's ability to resume any form of meaningful operations or business activity remains highly uncertain.

Risks to watch

• The primary risk is the complete absence of revenue generation, making profitability an unachievable goal.
• Auditors have flagged 'going concern' uncertainty, underscoring substantial doubts about the company's ability to continue operations.
• The negative net worth of ₹37 crore indicates a state of technical insolvency.
• Substantial disputed tax demands of over ₹24 Crore present a significant financial overhang.

Peer comparison

Finding direct listed peers for Gayatri BioOrganics Ltd in a comparable operational or financial crisis state is challenging. Most companies in the chemical and bio-organics sectors report active revenue streams and comparatively healthier balance sheets. The current zero-revenue status sets Gayatri BioOrganics apart as an entity facing existential challenges rather than operational competition.

Context metrics (time-bound)

• Net Loss for FY26 was ₹111.18 Lakhs (Standalone).
• Total disputed liabilities stand at over ₹24 Crores.
• Net Worth as of March 31, 2026, was ₹(3,700.49) Lakhs (Standalone).

What to track next

• Any update on the resolution or outcome of the disputed tax demands.
• Confirmation of whether promoters continue to provide funding and the extent of such support.
• Any strategic plans or announcements from the company regarding operational revival or restructuring.
• Future auditor reports for any changes in the 'going concern' assessment.
• Information on asset disposals or potential new acquisitions, if any.